10-Q: Allurion Faces Going Concern Amid Revenue Plunge, Restructures

Allurion Technologies reports a significant revenue decline and net loss, triggering a 'going concern' warning while pursuing strategic restructuring and new financing.

Summary

• Revenue for the nine months ended September 30, 2025, decreased by 56% to $11.617 million, down from $26.519 million in the same period of 2024.
• The company reported a net loss of $22.720 million for the nine months ended September 30, 2025, a significant shift from a net income of $2.410 million in the prior year period.
• Cash and cash equivalents decreased to $6.136 million as of September 30, 2025, from $15.379 million at December 31, 2024.
• Operating expenses decreased by 38.8% to $31.826 million for the nine months ended September 30, 2025, driven by reductions in sales and marketing (49%), research and development (51%), and general and administrative (22%).
• A strategic restructuring plan was initiated in August 2025, focusing on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry, involving a reduction in force of approximately 70 employees (65% of the workforce).
• The fourth and final module of the pre-market approval (PMA) application for the Allurion Program was submitted to the FDA on July 7, 2025, with additional supportive analyses from the AUDACITY trial.
• The company is not in compliance with the NYSE's Minimum Market Capitalization Standard as of August 29, 2024, but its remediation plan has been accepted, and it is subject to quarterly monitoring.
• An Exchange Agreement with RTW was entered into on November 11, 2025, where RTW will exchange its convertible notes and Revenue Interest Financing obligations for shares of a newly issued Series B convertible preferred stock, pending stockholder approval.

Sentiment

Score: 3

Explanation: The company faces severe financial challenges, including a substantial revenue decline, a shift to net loss, and a 'going concern' warning. Non-compliance with NYSE listing standards and ongoing litigation add to the negative sentiment. However, strategic restructuring, FDA PMA submission, and new financing efforts provide a glimmer of hope for future stability and growth, preventing an even lower score.

Positives

• Operating expenses decreased significantly by 38.8% for the nine months ended September 30, 2025, reflecting cost-saving measures from restructuring.
• Cash used in operating activities improved slightly, decreasing to $23.626 million for the nine months ended September 30, 2025, from $29.026 million in the prior year period.
• The fourth and final module of the FDA PMA application was submitted, with additional analyses showing the AUDACITY trial met both pre-specified co-primary endpoints after imputation methods.
• Allurion France successfully regained marketing authorization from ANSM on February 12, 2025, allowing the resumption of sales in France after a temporary suspension.
• The company secured new financing through a November 2025 Private Placement for approximately $5.0 million and an Exchange Agreement with RTW to convert debt into Series B Preferred Stock, addressing immediate liquidity concerns.

Negatives

• Revenue decreased by 56% to $11.617 million for the nine months ended September 30, 2025, primarily due to distributor transitions, reduced sales and marketing investment, and the temporary suspension of sales in France.
• The company reported a net loss of $22.720 million for the nine months ended September 30, 2025, a substantial decline from a net income of $2.410 million in the comparable prior year period.
• Cash and cash equivalents significantly decreased to $6.136 million as of September 30, 2025, from $15.379 million at December 31, 2024.
• The company has incurred recurring losses since inception and concluded there is substantial doubt about its ability to continue as a going concern for one year from the filing date.
• Allurion is not in compliance with the NYSE's Minimum Market Capitalization Standard ($50.0 million average market cap over 30 days) as of August 29, 2024.
• A reduction in force of approximately 70 employees (65% of the workforce) was implemented as part of a strategic restructuring, incurring an estimated $1.5 million in severance costs.
• Vanderbilt University Medical Center filed a complaint seeking $2.5 million for alleged breach of a Clinical Trial Agreement.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern within one year due to recurring losses, negative operating cash flows, and non-compliance with certain financial covenants.
• The company is not in compliance with the NYSE's Minimum Market Capitalization Standard and, while a plan has been accepted, it remains subject to quarterly monitoring for compliance.
• The strategic restructuring and reduction in force may not result in anticipated savings, could incur higher-than-expected costs, and may disrupt business operations, including employee retention and R&D activities.
• Ongoing litigation with Vanderbilt University Medical Center seeking $2.5 million for alleged breach of a Clinical Trial Agreement could result in material costs and adverse outcomes.
• Material weaknesses in internal control over financial reporting were identified, including insufficient segregation of duties, lack of public company/technical accounting experience, and insufficient information systems controls.
• Changes in U.S. federal tax laws, such as the 'One Big Beautiful Bill Act' (OBBBA) and Section 174 of the Internal Revenue Code (capitalization of R&D expenses performed outside the U.S.), could adversely affect cash flow.
• The company's ability to generate sufficient revenue and achieve profitability depends on successful further development, commercialization, and regulatory approvals of its products, which are uncertain.
• Failure to raise additional capital through equity or debt financings on favorable terms, or at all, could force the company to significantly delay, scale back, or discontinue operations and product development.

Future Outlook

The company expects to continue incurring net losses and negative operating cash flows for the foreseeable future as it focuses on obtaining regulatory approvals in new markets, refining sales and marketing strategies, and enhancing existing products. It anticipates needing additional funding through equity or debt financings to support operations and satisfy liquidity requirements. Key future milestones include obtaining FDA marketing authorization for U.S. commercialization by June 30, 2026, and beginning enrollment for a GLP-1 combination study this year.

Management Comments

• "We expect to continue to generate operating losses for the foreseeable future as we focus on obtaining regulatory approvals for our products in new markets, refining our sales and marketing strategies, and continuing research and development efforts to further enhance our existing products."
• "Our ability to generate revenue and achieve cost improvements sufficient to achieve profitability will depend on the successful further development and commercialization of our products and receipt and maintenance of regulatory approvals."
• "We believe the Allurion Program is also synergistic in combination with other weight loss therapies, including glucagon-like peptide 1 ('GLP-1') receptor agonists."
• "We have concluded that there is substantial doubt about our ability to continue as a going concern for a period of one year from the date that the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are issued."
• "We intend to defend against such claims vigorously, but we cannot be sure that we will be successful in prevailing in such proceeding or that it will not incur material costs in defending against such allegations."

Industry Context

Allurion Technologies is adapting to the evolving weight loss market by strategically focusing on low-dose GLP-1 combination therapy and muscle mass maintenance, indicating a response to the increasing prominence of GLP-1 receptor agonists in the industry. The company's efforts to expand into the U.S. market and transition to distribution partners with GLP-1 prescribing networks suggest a proactive approach to integrate with broader industry trends and enhance its competitive position in the rapidly changing weight management sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks. It mentions a 'comparable publicly traded peer index' in the context of the PIPE Conversion Option but does not detail specific metrics or entities for direct comparison.

Management Changes

Corporate Governance

Legal Proceedings

• On August 12, 2025, Vanderbilt University Medical Center filed a complaint against Allurion Technologies, Inc. in the United States District Court for the Middle District of Tennessee, alleging breach of a Clinical Trial Agreement and seeking approximately $2.5 million in damages for unreimbursed medical expenses.

Related Party Transactions

• RTW Investments, LP (and its affiliates) is a significant related party, involved in Convertible Notes, Revenue Interest Financing, PIPE Conversion Option, Public Offering participation, Private Placement, New RIFA, Second Amendment to Note Purchase Agreement, and an upcoming Exchange Agreement.
• Leavitt Equity Partners LLC (and its affiliates) participated in the Leavitt Private Placement and benefited from the February Warrant Repricing.
• A lease agreement for office space in Paris, France, was entered into with LNMP JPBC Invest, where the company's then-Trade Marketing Director was a signor and former Chief Commercial Officer is a partner. This lease was terminated in February 2024.

Stakeholder Impact

• Shareholders face significant dilution from multiple equity raises and warrant conversions, potential for further dilution, stock price volatility, and the risk of NYSE delisting due to non-compliance with market capitalization standards.
• Employees experienced a substantial reduction in force (approximately 65% of the workforce) as part of the strategic restructuring, impacting job security and potentially morale.
• Customers and healthcare providers may experience changes due to distributor transitions and the company's strategic shift towards GLP-1 combination therapies, potentially affecting product availability and support.
• Creditors, particularly RTW, are actively engaged in restructuring debt into equity, indicating a significant shift in the company's financial obligations and RTW's role as a key financial partner.
• The company's ability to continue as a 'going concern' directly impacts all stakeholders, raising fundamental questions about its long-term viability and ability to meet future obligations.

Next Steps

• Obtain stockholder approval for the issuance of shares upon exercise of November 2025 Private Placement Warrants (no later than January 31, 2026).
• Obtain stockholder approval for the issuance of Series B Preferred Stock in connection with the Exchange Agreement with RTW (no later than January 31, 2026).
• Continue remediation efforts for identified material weaknesses in internal control over financial reporting.
• Seek FDA marketing authorization for the commercialization of the Allurion Program in the United States (no later than June 30, 2026).
• Begin enrollment for a prospective, multi-center study on the combination of the Allurion Program with a low-dose of GLP-1 in Europe (expected this year).
• Vigorously defend against the legal complaint filed by Vanderbilt University Medical Center.

Key Dates

Recommendation

Allurion Technologies faces severe financial distress, evidenced by a 56% revenue decline, a shift from net income to a substantial net loss, and an explicit 'going concern' warning from management. The company is not in compliance with NYSE listing standards, indicating significant market value erosion. While strategic restructuring and new financing efforts are underway, these are reactive measures to a deteriorating financial position and carry execution risks. The ongoing litigation and identified material weaknesses in internal controls further compound the negative outlook. Given the high level of uncertainty, significant cash burn, and fundamental questions about long-term viability, a seasoned investor would likely recommend a strong sell.

Keywords

Weight Loss, Medical Device, Intragastric Balloon, Allurion Smart Capsule, GLP-1, FDA Approval, SEC Filing, 10-Q, Financial Results, Restructuring, Going Concern, NYSE Listing, Capital Raise, RTW Investments, Clinical Trials